Content about Head and neck cancer

August 3, 2012

TV news station CBS Philly reports how Walgreen's Take Care Clinic nurse practitioner Renee Corradetti noticed an abnormality in a patient's throat, which later led to a diagnosis of an aggressive form of throat cancer.

TV news station CBS Philly reports how Walgreen's Take Care Clinic nurse practitioner Renee Corradetti noticed an abnormality in a patient's throat, which later led to a diagnosis of an aggressive form of throat cancer and life-saving chemotherapy treatments.

July 9, 2012

The Food and Drug Administration has approved a drug made by Eli Lilly and Bristol-Myers Squibb for treating a form of colorectal cancer, the two companies said.

NEW YORK — The Food and Drug Administration has approved a drug made by Eli Lilly and Bristol-Myers Squibb for treating a form of colorectal cancer, the two companies said.

Lilly and Bristol announced the approval of Erbitux (cetuximab) for treating colorectal cancer that is KRAS mutation-negative, expresses the epidermal growth factor receptor and has spread to other parts of the body, also known as metastasis. The drug is approved for use alongside a chemotherapy combination containing irinotecan, 5-fluorouracil and leucovorin, also known as FOLFIRI.

November 7, 2011

The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb for treating head and neck cancer, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb and Eli Lilly & Co. for treating head and neck cancer, the agency said Monday.

The FDA announced the approval of Erbitux (cetuximab) for use with chemotherapy in treating head and neck cancer that had spread to other parts of the body. The drug originally was approved in 2004 for treating certain cases of late-stage colon cancer in patients who had stopped responding to chemotherapy.

August 11, 2010

An investigational biotech drug didn’t significantly improve patients’ survival, according to results of a late-stage...

May 20, 2010

Data from a late-stage clinical trial of an investigational drug by Boehringer Ingelheim could show...